Guest Post
Photo Credit: www.pexels.com
Innovations in Drug Development and Delivery for Epilepsy
Epilepsy is a chronic, noncommunicable brain disorder that affects individuals across all age groups.
According to the WHO, approximately 50 million people worldwide live with epilepsy, making it one of the most prevalent neurological conditions globally. Despite its widespread impact, up to 70% of those affected could potentially achieve seizure-free lives with accurate diagnosis and appropriate treatment.
However, treatment gaps, side effects, and drug resistance continue to challenge current therapeutic approaches. As a result, innovations in drug development and delivery are emerging as critical avenues for improving patient outcomes.
From targeted therapies to advanced delivery systems, these breakthroughs offer renewed hope for more effective, personalized, and accessible epilepsy care.
Advances in Drug Development
Epilepsy research is increasingly moving towards precision medicine, developing therapies that target the specific genetic or molecular underpinnings of a patient’s seizures. Unlike traditional antiepileptic drugs (AEDs) that broadly suppress neural activity, these novel treatments aim to address the precise mechanisms of particular epilepsies.
When epilepsy’s genetic cause is known, treatments can be tailored to control seizures and improve quality of life, including cognitive and behavioral symptoms.
Recent breakthroughs include:
- Gene-targeted treatments: Innovative therapies like antisense oligonucleotides for specific syndromes (e.g., Dravet syndrome) are showing promising disease-modifying potential in early studies.
- Targeted enzyme inhibitors and ion channel modulators: New molecules are being designed for precise neural excitability modulation, aiming to reduce side effects and maximize efficacy for difficult-to-treat seizures.
- Regenerative medicine approaches: Cell and gene therapies, such as allogeneic neural cell transplantation, are entering trials for patients with drug-resistant epilepsy, offering hope for neural repair.
These advancements are fueling significant market growth. According to Pharmiweb.com, the global epilepsy drugs market, valued at USD 10.63 billion in 2024, is projected to reach USD 20.5 billion by 2035. This expansion is supported by the rise of precision medicine, favorable regulatory frameworks, and public-private investment in neurological research.
Despite these promising developments, obtaining high-level clinical evidence remains challenging due to the complexity of individual cases.
Emergence of Novel Drug Delivery Systems
Innovative delivery technologies are revolutionizing how antiepileptic drugs (AEDs) reach their targets and maintain effective concentrations in the brain. Traditional oral medications face limitations such as first-pass metabolism, uneven drug levels, and poor blood-brain barrier (BBB) penetration.
Modern strategies aim to overcome these barriers and optimize therapy. They include:
- Nanoparticle-based systems: Encapsulating drugs within nanoparticles allows for controlled and targeted release, efficiently crossing the blood-brain barrier (BBB).
This method prolongs drug action and may reduce side effects by directing therapy precisely where it’s needed.
- Stimuli-responsive delivery: Nanoengineered platforms are being developed to release medication only in response to specific triggers, like abnormal electrical activity during a seizure. These “on-demand” systems promise minimal drug exposure with timely intervention.
- Transdermal and intranasal delivery: New formulations via skin patches or nasal sprays bypass gastrointestinal absorption, offering alternatives for those unable to take oral drugs.
- Green and biotechnological synthesis: Eco-friendly fabrication of delivery vehicles using biocompatible materials enhances safety and minimizes long-term adverse effects.
Additionally, according to Frontiers, several strategies to bypass the BBB, like magnetic resonance-guided low-intensity focused ultrasound (FUS), show great potential for brain drug delivery. Preliminary clinical trials have shown that FUS can reversibly open the BBB in critical brain regions associated with epilepsy, such as the hippocampus.
This breakthrough paves the way for the precise delivery of high-dose therapies and marks a significant advancement in the field.
The Critical Role of Healthcare Professionals
The success of innovative epilepsy treatments depends on scientific breakthroughs and on the healthcare professionals who translate these advancements into practical care. From neurologists who diagnose and manage epilepsy to nurses who provide support, each member of the care team plays a vital role.
Among them, pharmacists and pharmacologists are increasingly central to improving outcomes through precision medicine and novel drug delivery systems.
While the general public is more familiar with pharmacists, often seen in clinics or community pharmacies, pharmacologists work more behind the scenes. According to the University of Findlay, both make significant contributions to public health. However, pharmacologists are rarely mentioned in professional rankings due to the niche nature of their roles.
Understanding the difference between pharmacology vs pharmacy is essential. Pharmacology is the scientific study of how drugs affect biological systems, focusing on discovery, development, and therapeutic mechanisms. Pharmacologists drive innovation by studying antiepileptic drugs at the molecular level.
Pharmacy, on the other hand, is a healthcare profession centered on the safe, effective use of medications. As novel delivery systems emerge, pharmacists also play a key role in guiding patients on their use.
Together, these professionals ensure that cutting-edge epilepsy treatments are both accessible and optimized for individual needs.
Future Directions and Emerging Technologies
According to Nature, current antiseizure medications (ASMs) fail to control seizures in at least 30% of patients. However, advances in epilepsy genetics and the development of new disease models have significantly deepened our understanding of the condition. As a result, more than 200 new therapies are now in the preclinical or clinical pipeline.
Gene therapies are under investigation for genetic forms of epilepsy, offering the possibility of curative treatments rather than just symptom control. Cell-based approaches like stem cell therapy and optogenetics are poised to revolutionize care by targeting the root causes of seizures. Artificial intelligence is also accelerating drug discovery and helping personalize treatment protocols.
Meanwhile, nanotechnology offers improved brain drug delivery, using nanoparticles to cross the blood-brain barrier and target specific regions while reducing side effects. Wearable devices and digital health tools are being integrated into drug delivery systems, allowing for real-time monitoring and individualized treatment adjustments.
Frequently Asked Questions
What is the new drug for epilepsy in 2025?
In 2025, fenfluramine was approved for NHS patients with Lennox-Gastaut syndrome (LGS). Starting 20 February 2025, NICE recommends it for treating seizures in individuals aged two and over. This offers a new option for managing this severe form of epilepsy and improving patient outcomes.
Is there a 100% cure for epilepsy?
There is currently no 100% cure for epilepsy. However, with accurate diagnosis and proper treatment, up to 70% of people with epilepsy can live seizure-free. Advances in therapies, including surgery, medications, and emerging technologies, continue to improve outcomes, but complete eradication of the condition is not yet guaranteed.
What is the new epilepsy device?
The new epilepsy device, EASEE (Epicranial Application of Stimulation Electrodes for Epilepsy), was developed by Precisis. Implanted just under the scalp over the seizure focus, EASEE delivers high-frequency electrical pulses every two seconds. These pulses disrupt emerging seizures, offering a promising non-invasive treatment for drug-resistant epilepsy.
Innovations in epilepsy drug development and delivery are redefining the possibilities for seizure control and quality of life. Advances in precision medicine, nanoengineering, and smart delivery systems are complementing the critical, patient-centered contributions of pharmacists and clinical teams.
By harnessing both scientific expertise and practical care, the epilepsy community moves closer to the goal of effective and safe management for all patients.
Resources:
Klein, P., Kaminski, R.M., Koepp, M. et al. New epilepsy therapies in development. Nat Rev Drug Discov 23, 682–708 (2024). https://doi.org/10.1038/s41573-024-00981-w
Pharmiweb.com (2025). Understanding the Growth of the Epilepsy Drugs Industry by 2035. Pharmiweb.com. Retrieved from: https://www.pharmiweb.com/press-release/2025-07-15/understanding-the-growth-of-the-epilepsy-drugs-industry-by-2035
University of Findlay (2026). Pharmacist vs. Pharmacologist: What Makes Them Different? University of Findlay. Retrieved from: https://pharmdonline.findlay.edu/blog/pharmacist-pharmacologist
